Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Reply to: Deconvoluting COPD: Are B Cells the Frontrunners?

Ladjemi MZ, Burgel PR, Pilette C.

Am J Respir Crit Care Med. 2019 Jan 11. doi: 10.1164/rccm.201812-2249LE. [Epub ahead of print] No abstract available.

PMID:
30633554
2.

Cluster and CART analyses identify large subgroups of adults with cystic fibrosis at low risk of 10-year death.

Burgel PR, Lemonnier L, Dehillotte C, Sykes J, Stanojevic S, Stephenson AL, Paillasseur JL.

Eur Respir J. 2018 Dec 21. pii: 1801943. doi: 10.1183/13993003.01943-2018. [Epub ahead of print]

PMID:
30578399
3.

Automated computed tomographic scoring of lung disease in adults with primary ciliary dyskinesia.

Hoang-Thi TN, Revel MP, Burgel PR, Bassinet L, Honoré I, Hua-Huy T, Martin C, Maitre B, Chassagnon G.

BMC Pulm Med. 2018 Dec 18;18(1):194. doi: 10.1186/s12890-018-0758-6.

4.

[Respiratory Medicine and Research: The new SPLF's anglophone journal].

Burgel PR, Montani D, Pigearias B, Blanc FX, Roche N.

Rev Pneumol Clin. 2018 Dec;74(6):367-368. doi: 10.1016/j.pneumo.2018.11.001. French. No abstract available.

PMID:
30527221
5.

Acute and chronic non-pulmonary complications in adults with cystic fibrosis.

Regard L, Martin C, Chassagnon G, Burgel PR.

Expert Rev Respir Med. 2019 Jan;13(1):23-38. doi: 10.1080/17476348.2019.1552832. Epub 2018 Nov 30.

PMID:
30472915
6.

Validation of the French 3-year prognostic score using the Canadian Cystic Fibrosis registry.

Coriati A, Sykes J, Nkam L, Hocine MN, Burgel PR, Stephenson AL.

J Cyst Fibros. 2018 Nov 2. pii: S1569-1993(18)30911-1. doi: 10.1016/j.jcf.2018.10.014. [Epub ahead of print]

PMID:
30396836
7.

[Acute pulmonary and non-pulmonary complications in adults with cystic fibrosis].

Lafoeste H, Regard L, Martin C, Chassagnon G, Burgel PR.

Rev Pneumol Clin. 2018 Oct;74(5):267-278. doi: 10.1016/j.pneumo.2018.09.004. Epub 2018 Oct 19. French.

PMID:
30343944
8.

Increased IgA Expression in Lung Lymphoid Follicles in Severe COPD.

Ladjemi MZ, Martin C, Lecocq M, Detry B, Aboubakar Nana F, Moulin C, Weynand B, Fregimilicka C, Bouzin C, Thurion P, Carlier F, Serré J, Gayan-Ramirez G, Delos M, Ocak S, Burgel PR, Pilette C.

Am J Respir Crit Care Med. 2018 Oct 19. doi: 10.1164/rccm.201802-0352OC. [Epub ahead of print]

PMID:
30339768
9.

[Bronchiectasis in adults: Etiological diagnosis].

Martin C, Regard L, Chassagnon G, Burgel PR.

Rev Pneumol Clin. 2018 Oct;74(5):292-298. doi: 10.1016/j.pneumo.2018.09.011. Epub 2018 Oct 11. French.

PMID:
30318255
10.

[Ageing with cystic fibrosis: Classical and emerging comorbidities in adults with cystic fibrosis].

Regard L, Lafoeste H, Martin C, Chassagnon G, Burgel PR.

Rev Pneumol Clin. 2018 Oct;74(5):279-291. doi: 10.1016/j.pneumo.2018.09.012. Epub 2018 Oct 11. French.

PMID:
30316653
11.

[Personalised COPD care: Where are we going?]

Roche N, Martin C, Burgel PR.

Rev Pneumol Clin. 2018 Oct;74(5):315-326. doi: 10.1016/j.pneumo.2018.09.003. Epub 2018 Oct 11. French.

PMID:
30316649
12.

Exploring the Role of Tertiary Lymphoid Structures Using a Mouse Model of Bacteria-Infected Lungs.

Teillaud JL, Regard L, Martin C, Sibéril S, Burgel PR.

Methods Mol Biol. 2018;1845:223-239. doi: 10.1007/978-1-4939-8709-2_13.

PMID:
30141016
13.

An attempt at modeling COPD epidemiological trends in France.

Burgel PR, Laurendeau C, Raherison C, Fuhrman C, Roche N.

Respir Res. 2018 Jun 27;19(1):130. doi: 10.1186/s12931-018-0827-7.

14.

An automated computed tomography score for the cystic fibrosis lung.

Chassagnon G, Martin C, Burgel PR, Hubert D, Fajac I, Paragios N, Zacharaki EI, Legmann P, Coste J, Revel MP.

Eur Radiol. 2018 Dec;28(12):5111-5120. doi: 10.1007/s00330-018-5516-x. Epub 2018 Jun 4.

PMID:
29869171
15.

Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis.

De Rose V, Burgel PR, Gaggar A, Greene C.

Mediators Inflamm. 2018 May 2;2018:7280747. doi: 10.1155/2018/7280747. eCollection 2018. No abstract available.

16.

Cured bronchi! Extending the use of nebulised hypertonic saline outside of cystic fibrosis?

Martin C, Regard L, Burgel PR.

Eur Respir J. 2018 May 17;51(5). pii: 1800755. doi: 10.1183/13993003.00755-2018. Print 2018 May. No abstract available.

PMID:
29773609
17.

A prospective analysis of unplanned patient-initiated contacts in an adult cystic fibrosis centre.

Burnet E, Hubert D, Champreux J, Honoré I, Kanaan R, Panzo R, Burgel PR.

J Cyst Fibros. 2018 Sep;17(5):636-642. doi: 10.1016/j.jcf.2018.04.006. Epub 2018 May 8.

PMID:
29748153
18.

Peribronchial tertiary lymphoid structures persist after rituximab therapy in patients with cystic fibrosis.

Regard L, Martin C, Zemoura L, Geolier V, Sage E, Burgel PR.

J Clin Pathol. 2018 Aug;71(8):752-753. doi: 10.1136/jclinpath-2018-205160. Epub 2018 Apr 27. No abstract available.

PMID:
29703760
19.

[Lower limit of normal vs. fixed ratio for the diagnosis of COPD: Is it that important?]

Burgel PR.

Rev Mal Respir. 2018 Mar;35(3):235-237. doi: 10.1016/j.rmr.2018.04.003. French. No abstract available.

PMID:
29699778
20.

Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.

Biton J, Ouakrim H, Dechartres A, Alifano M, Mansuet-Lupo A, Si H, Halpin R, Creasy T, Bantsimba-Malanda C, Arrondeau J, Goldwasser F, Boudou-Rouquette P, Fournel L, Roche N, Burgel PR, Goc J, Devi-Marulkar P, Germain C, Dieu-Nosjean MC, Cremer I, Herbst R, Damotte D.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):928-940. doi: 10.1164/rccm.201706-1110OC.

PMID:
29518341
21.

Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease.

Guerra B, Haile SR, Lamprecht B, Ramírez AS, Martinez-Camblor P, Kaiser B, Alfageme I, Almagro P, Casanova C, Esteban-González C, Soler-Cataluña JJ, de-Torres JP, Miravitlles M, Celli BR, Marin JM, Ter Riet G, Sobradillo P, Lange P, Garcia-Aymerich J, Antó JM, Turner AM, Han MK, Langhammer A, Leivseth L, Bakke P, Johannessen A, Oga T, Cosio B, Ancochea-Bermúdez J, Echazarreta A, Roche N, Burgel PR, Sin DD, Soriano JB, Puhan MA; 3CIA collaboration.

BMC Med. 2018 Mar 2;16(1):33. doi: 10.1186/s12916-018-1013-y.

22.

On Don Quixote and pink puffers: multi-organ loss of tissue COPD.

Soriano JB, Burgel PR.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702560. doi: 10.1183/13993003.02560-2017. Print 2018 Feb. No abstract available.

PMID:
29437949
23.

Blood eosinophil counts as a guide for COPD treatment strategies.

Roche N, Zysman M, Burgel PR.

Lancet Respir Med. 2018 Feb;6(2):78-80. doi: 10.1016/S2213-2600(18)30005-5. Epub 2018 Jan 10. No abstract available.

PMID:
29331310
24.

The Major Chromoblastomycosis Etiologic Agent Fonsecaea pedrosoi Activates the NLRP3 Inflammasome.

de Castro RJA, Siqueira IM, Jerônimo MS, Basso AMM, Veloso Junior PHH, Magalhães KG, Leonhardt LC, de Oliveira SAM, Bürgel PH, Tavares AH, Bocca AL.

Front Immunol. 2017 Nov 20;8:1572. doi: 10.3389/fimmu.2017.01572. eCollection 2017.

25.

A simple algorithm for the identification of clinical COPD phenotypes.

Burgel PR, Paillasseur JL, Janssens W, Piquet J, Ter Riet G, Garcia-Aymerich J, Cosio B, Bakke P, Puhan MA, Langhammer A, Alfageme I, Almagro P, Ancochea J, Celli BR, Casanova C, de-Torres JP, Decramer M, Echazarreta A, Esteban C, Gomez Punter RM, Han MK, Johannessen A, Kaiser B, Lamprecht B, Lange P, Leivseth L, Marin JM, Martin F, Martinez-Camblor P, Miravitlles M, Oga T, Sofia Ramírez A, Sin DD, Sobradillo P, Soler-Cataluña JJ, Turner AM, Verdu Rivera FJ, Soriano JB, Roche N; Initiatives BPCO, EABPCO, Leuven and 3CIA study groups.

Eur Respir J. 2017 Nov 2;50(5). pii: 1701034. doi: 10.1183/13993003.01034-2017. Print 2017 Nov.

PMID:
29097431
26.

Staining and Clearing of Arabidopsis Reproductive Tissue for Imaging of Fluorescent Proteins.

Slane D, Bürgel P, Bayer M.

Methods Mol Biol. 2017;1669:87-94. doi: 10.1007/978-1-4939-7286-9_8.

PMID:
28936652
27.

A first step to STOP cystic fibrosis exacerbations.

Burgel PR, Reid DW, Aaron SD.

J Cyst Fibros. 2017 Sep;16(5):529-531. doi: 10.1016/j.jcf.2017.08.006. No abstract available.

PMID:
28865768
28.

Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis.

Burgel PR, Bellis G, Elborn JS.

Eur Respir J. 2017 Aug 3;50(2). pii: 1700763. doi: 10.1183/13993003.00763-2017. Print 2017 Aug. No abstract available.

PMID:
28775048
29.

Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis.

Marteyn BS, Burgel PR, Meijer L, Witko-Sarsat V.

Front Cell Infect Microbiol. 2017 Jun 30;7:243. doi: 10.3389/fcimb.2017.00243. eCollection 2017. Review.

30.

Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD.

Zysman M, Deslee G, Caillaud D, Chanez P, Escamilla R, Court-Fortune I, Nesme-Meyer P, Perez T, Paillasseur JL, Pinet C, Jebrak G, Roche N, Burgel PR.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 20;12:1819-1824. doi: 10.2147/COPD.S129787. eCollection 2017.

31.

Cystic fibrosis: Current aspects and perspectives.

Burgel PR, Fajac I.

Presse Med. 2017 Jun;46(6 Pt 2):e85-e86. doi: 10.1016/j.lpm.2017.06.001. French. No abstract available.

PMID:
28641709
32.

[Changing patterns of medication prescription for COPD patients in France. Impact of long-acting muscarinic antagonists' availability].

Jébrak G, Burgel PR, Caillaud D, Deslée G, Brinchault G, Chanez P, Court-Fortune I, Escamilla R, Nesme-Meyer P, Pinet C, Perez T, Paillasseur JL, Roche N; pour le groupe Initiatives BPCO.

Rev Mal Respir. 2017 May;34(5):535-543. doi: 10.1016/j.rmr.2017.02.006. Epub 2017 May 31. French.

PMID:
28578989
33.

The changing epidemiology and demography of cystic fibrosis.

Stephenson AL, Stanojevic S, Sykes J, Burgel PR.

Presse Med. 2017 Jun;46(6 Pt 2):e87-e95. doi: 10.1016/j.lpm.2017.04.012. Epub 2017 May 26.

PMID:
28554720
34.

Management of acute exacerbations of chronic obstructive pulmonary disease (COPD). Guidelines from the Société de pneumologie de langue française (summary).

Jouneau S, Dres M, Guerder A, Bele N, Bellocq A, Bernady A, Berne G, Bourdin A, Brinchault G, Burgel PR, Carlier N, Chabot F, Chavaillon JM, Cittee J, Claessens YE, Delclaux B, Deslée G, Ferré A, Gacouin A, Girault C, Ghasarossian C, Gouilly P, Gut-Gobert C, Gonzalez-Bermejo J, Jebrak G, Le Guillou F, Léveiller G, Lorenzo A, Mal H, Molinari N, Morel H, Morel V, Noel F, Pégliasco H, Perotin JM, Piquet J, Pontier S, Rabbat A, Revest M, Reychler G, Stelianides S, Surpas P, Tattevin P, Roche N.

Rev Mal Respir. 2017 Apr;34(4):282-322. doi: 10.1016/j.rmr.2017.03.034. Epub 2017 May 25.

PMID:
28552256
35.

[Impact of acute COPD exacerbation and repetitive episodes on the disease evolution].

Burgel PR.

Rev Mal Respir. 2017 Apr;34(4):331-337. doi: 10.1016/j.rmr.2017.03.003. Epub 2017 May 2. Review. French. No abstract available.

PMID:
28476419
36.

Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis.

Frija-Masson J, Martin C, Regard L, Lothe MN, Touqui L, Durand A, Lucas B, Damotte D, Alifano M, Fajac I, Burgel PR.

Eur Respir J. 2017 Apr 26;49(4). pii: 1601873. doi: 10.1183/13993003.01873-2016. Print 2017 Apr.

37.

A 3-year prognostic score for adults with cystic fibrosis.

Nkam L, Lambert J, Latouche A, Bellis G, Burgel PR, Hocine MN.

J Cyst Fibros. 2017 Nov;16(6):702-708. doi: 10.1016/j.jcf.2017.03.004. Epub 2017 Mar 18.

38.

Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease.

Hubert D, Chiron R, Camara B, Grenet D, Prévotat A, Bassinet L, Dominique S, Rault G, Macey J, Honoré I, Kanaan R, Leroy S, Desmazes Dufeu N, Burgel PR.

J Cyst Fibros. 2017 May;16(3):388-391. doi: 10.1016/j.jcf.2017.03.003. Epub 2017 Mar 18.

PMID:
28325531
39.

[New therapeutic developments in cystic fibrosis].

Bui S, Macey J, Fayon M; « nouvelles thérapeutiques de la Société Française pour la Mucoviscidose », Bihouée T, Burgel PR, Colomb V, Corvol H, Durieu I, Hubert D, Marguet C, Mas E, Munck A, Murris-Espin M, Reix P, Sermet-Gaudelus I.

Arch Pediatr. 2016 Dec;23(12S):12S47-12S53. doi: 10.1016/S0929-693X(17)30062-3. Review. French.

PMID:
28231894
40.

[Epidemiological trends of cystic fibrosis in France: 10-year perspective].

Burgel PR.

Arch Pediatr. 2016 Dec;23(12S):12S4-12S8. doi: 10.1016/S0929-693X(17)30056-8. Review. French.

PMID:
28231893
41.

Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease.

Burgel PR, Le Gros V, Decuypère L, Bourdeix I, Perez T, Deslée G.

BMC Pulm Med. 2017 Jan 31;17(1):25. doi: 10.1186/s12890-017-0372-z.

42.

How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

Beeh KM, Burgel PR, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR, Fležar M, Ulrik CS, Di Marco F, Stolz D, Valipour A, Casserly B, Ställberg B, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Jul 15;196(2):139-149. doi: 10.1164/rccm.201609-1794CI. Review.

43.

DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.

Viel M, Hubert D, Burgel PR, Génin E, Honoré I, Martinez B, Gaitch N, Chapron J, Kanaan R, Dusser D, Girodon E, Bienvenu T.

Clin Respir J. 2016 Nov;10(6):777-783. doi: 10.1111/crj.12288. Epub 2015 Apr 15.

PMID:
25763772
44.

A Rapid and Simple Method for Microscopy-Based Stomata Analyses.

Eisele JF, Fäßler F, Bürgel PF, Chaban C.

PLoS One. 2016 Oct 12;11(10):e0164576. doi: 10.1371/journal.pone.0164576. eCollection 2016.

45.

Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients.

Nové-Josserand R, Grard S, Auzou L, Reix P, Murris-Espin M, Brémont F, Mammar B, Mely L, Hubert D, Durieu I, Burgel PR.

Pediatr Pulmonol. 2017 Feb;52(2):190-197. doi: 10.1002/ppul.23612. Epub 2016 Oct 7.

PMID:
27717223
46.

Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy.

Burgel PR, Paugam A, Hubert D, Martin C.

Infect Drug Resist. 2016 Sep 20;9:229-238. eCollection 2016. Review.

47.

Impact of current cough on health-related quality of life in patients with COPD.

Deslee G, Burgel PR, Escamilla R, Chanez P, Court-Fortune I, Nesme-Meyer P, Brinchault-Rabin G, Perez T, Jebrak G, Caillaud D, Paillasseur JL, Roche N.

Int J Chron Obstruct Pulmon Dis. 2016 Sep 13;11:2091-2097. eCollection 2016.

48.

Toward Personalized Prescription of Systemic Steroids for Patients Hospitalized With COPD Exacerbations.

Burgel PR.

Chest. 2016 Aug;150(2):268-9. doi: 10.1016/j.chest.2016.03.028. No abstract available.

PMID:
27502977
49.

Asthma-COPD overlap syndrome (ACOS) vs 'pure' COPD: a distinct phenotype?

Caillaud D, Chanez P, Escamilla R, Burgel PR, Court-Fortune I, Nesme-Meyer P, Deslee G, Perez T, Paillasseur JL, Pinet C, Jebrak G, Roche N; Initiatives BPCO scientific committee and investigators.

Allergy. 2017 Jan;72(1):137-145. doi: 10.1111/all.13004. Epub 2016 Sep 27.

PMID:
27501862
50.

Limitations to providing adult cystic fibrosis care in Europe: Results of a care centre survey.

Madge S, Bell SC, Burgel PR, De Rijcke K, Blasi F, Elborn JS; ERS/ECFS task force: The provision of care for adults with cystic fibrosis in Europe.

J Cyst Fibros. 2017 Jan;16(1):85-88. doi: 10.1016/j.jcf.2016.07.001. Epub 2016 Jul 26.

Supplemental Content

Loading ...
Support Center